Sumitovant Biopharma Ltd., i le faiga faapaaga ma lona matua kamupani Sumitomo Dainippon Pharma Co., Ltd., na faasilasila talu ai nei le faalauiloaina o se vaega 1 suesuega i le US i luga o se sui fou fualaau faasaina (“KSP-1007”) mo siama siama e tetee i le carbapenem. . O le faʻalauiloaina o se taunuuga o se suʻesuʻega faʻatasi i le va o Sumitomo Dainippon Pharma ma le Kitasato Institute i Iapani. Sumitvant o loʻo taʻitaʻia le polokalame o le faʻalapotopotoga i le US o loʻo tulimataʻia le lavelave o le urinary tract ma totonu o le manava.

"O loʻo i ai se manaʻoga faʻafomaʻi maualuga e leʻi ausia mo togafitiga lelei o faʻamaʻi lavelave i le lalolagi atoa," o le tala lea a Myrtle Potter, Pule Sili o Sumitvant. "O le atinaʻeina o togafitiga faʻamaʻi faʻamaʻi e leʻi sili atu ona taua pe faanatinati. Ou te talitonu o lenei sui tauva e mafai ona avea ma se togafitiga lelei e tetee atu ai i faʻamaʻi pipisi o le carbapenem e aʻafia ai le tele o tagata i le US ma tua atu.

O fa'ama'i fa'ama'i fa'ama'i o se tasi lea o mafua'aga masani o le sepsis. O faʻamaʻi lavelave o faʻamaʻi ia e maualuga atu le lamatiaga o le le manuia o togafitiga ma e masani ona manaʻomia le umi o aʻoaʻoga faʻamaʻi. O fa'ama'i lavelave i totonu o le manava o fa'ama'i ia e o'o atu i tua atu o le puipui o se viscus ga'o na afua mai i totonu o le manava a'o feso'ota'i ma se abscess po'o le peritonitis.

"E foliga mai i faʻamatalaga e le faʻapitoa e faʻapea KSP-1007 lautele ma malosi faʻalavelave β-lactamases, o enzymes ia e gaosia e siama e mafai ona faʻaleagaina ai vailaʻau o le carbapenem," o le tala lea a Salomon Azoulay, MD Chief Medical Officer ma Ulu o Suesuega & Atinaʻe i Sumitvant, o lana 'au o loʻo taʻitaʻia le mamanu ma le faʻatinoina o le vaega 1 suʻesuʻega i le US "O loʻo matou suʻesuʻeina KSP-1007 faʻatasi ma le meropenem hydrate, o se vailaʻau carbapenem, ua uma ona faʻaaogaina e togafitia ai faʻamaʻi Gram (-), e faʻaleleia ai le aoga i le faigata. fa'ama'i pipisi i totonu ole manava."

O le atina'eina o vailaau fa'ama'i fou ose mataupu fa'avaomalo fa'anatinati. O le tula'i mai ma le fa'asalalauina o siama fa'aantimicrobial resistant (AMR), lea e tete'e i vaila'au fa'ama'i, ose fa'afitauli fa'alelalolagi fa'atupula'ia ma popolega. Ua fuafuaina e le Faletupe a le Lalolagi e 700,000 tagata e feoti i siama siama o le AMR i tausaga taʻitasi.1 Ua valaʻau le Faalapotopotoga o le Soifua Maloloina a le Lalolagi mo ni faiga faʻanatinati i le atunuʻu ma le lalolagi atoa e tetee atu ai i nei faʻamaʻi ma atiaʻe togafitiga fou. Ona o le faʻateleina o le faʻaaogaina o vailaʻau faʻamaʻi e fesoʻotaʻi ma le COVID-19, o loʻo iai le popolega o siama faʻamaʻi faʻamaʻi faʻamaʻi o le a sili atu ona sosolo.

Sumitomo ma Sumitomo Dainippon Pharma ua tuuto atu i le sailia o ni togafitiga fou mo togafitiga sili ona luitauina ma tulaga i le lalolagi atoa. O le atina'eina o togafitiga fa'ama'i fa'ama'i fou o se tasi lea o vaega e taula'i i ai le au su'esu'e a kamupani.

OA MEA E AVEA MAI LENEI TUSI:

I believe this drug candidate has the potential to be an effective treatment option against carbapenem-resistant bacterial infections that affect so many people in the U.
Complicated intra-abdominal infections are infections that extend beyond the wall of a hollow viscus of origin into the abdominal cavity while being associated with an abscess or peritonitis.
The launch is a result of a joint research project between Sumitomo Dainippon Pharma and the Kitasato Institute in Japan.